Filter Results
:
(920)
Show Results For
-
All HBS Web
(920)
- People (2)
- News (61)
- Research (752)
- Events (1)
- Multimedia (2)
- Faculty Publications (643)
Show Results For
-
All HBS Web
(920)
- People (2)
- News (61)
- Research (752)
- Events (1)
- Multimedia (2)
- Faculty Publications (643)
- Web
Strategy Awards & Honors - Faculty & Research
in the future." 2022 Alexander J. MacKay: Awarded the 2022 Robert F. Lanzillotti Prize for Best Paper in Antitrust Economics at the International Industrial Organization Conference for "Rising Markups and the Role of Consumer Preferences"...
View Details
- Web
2022 Reunion Presentations - Alumni
Senior Lecturer Kristin W. Mugford (MBA 1993) + More Info – Less Info Over the last decade, firms have begun to recognize the power of gender diversity and have worked to actively hire and retain more women. While we see improved diversity at junior levels, View Details
- June 2004 (Revised June 2006)
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (A)
By: Gary P. Pisano, Lee Fleming and Eli Strick
Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will...
View Details
Pisano, Gary P., Lee Fleming, and Eli Strick. "Vertex Pharmaceuticals: R&D Portfolio Management (A)." Harvard Business School Supplement 604-101, June 2004. (Revised June 2006.)
- 27 May 2009
- First Look
First Look: May 27, 2009
industry and services. Although each Mubadala investment is supposed to earn large returns, the strategy balances financial against "strategic" returns. ADIA and Mubadala are the institutional architecture to manage the wealth...
View Details
Keywords:
Martha Lagace
- 15 Jun 2007
- Research & Ideas
Remembering Alfred Chandler
great-grandfather, the business editor and analyst Henry Varnum Poor, to 2 recent volumes, published while he was in his 80s: Inventing the Electronic Century: The Epic Story of the Consumer Electronics and Computer Industries and Shaping...
View Details
Keywords:
by Sean Silverthorne
- May 1998 (Revised May 1999)
- Case
Biopure Corp.
It is early 1998 and Biopure Corp., a small biopharmaceutical firm with no sales revenues in its ten-year history, has just received government approval to release Oxyglobin, a revolutionary new "blood substitute" designed to replace the need for donated animal blood...
View Details
Keywords:
Segmentation;
Marketing Strategy;
Engineering;
Budgets and Budgeting;
Sales;
Transformation;
Markets;
Debates;
Product Launch;
Pharmaceutical Industry
Gourville, John T. "Biopure Corp." Harvard Business School Case 598-150, May 1998. (Revised May 1999.)
- September 2010 (Revised July 2013)
- Case
Alnylam Pharmaceuticals: Building Value from the IP Estate
By: Willy C. Shih and Sen Chai
The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it...
View Details
Keywords:
Patents;
Lawsuits and Litigation;
Rights;
Competitive Strategy;
Corporate Strategy;
Biotechnology Industry;
Biotechnology Industry;
United States
Shih, Willy C., and Sen Chai. "Alnylam Pharmaceuticals: Building Value from the IP Estate." Harvard Business School Case 611-009, September 2010. (Revised July 2013.)
- 31 Jan 2014
- News
Body, Heal Thyself
for the development and exclusive use of the mRNA technology to treat cardiovascular, renal, and metabolic diseases as well as cancer. "It is one of the largest-ever initial payments in a pharmaceutical View Details
- April 2011 (Revised April 2015)
- Case
Cipla 2011
By: Rohit Deshpande, Sandra J. Sucher and Laura Winig
Dr. Yusuf Hamied, head of the Indian pharma and generics manufacturing company Cipla, is weighing options for how to continue to support the global fight against HIV/AIDS while positioning his company for growth in a changing regulatory landscape.
View Details
Keywords:
Leadership;
Leading Change;
Leadership Style;
Management Teams;
Governance Compliance;
Corporate Strategy;
Pharmaceutical Industry
Deshpande, Rohit, Sandra J. Sucher, and Laura Winig. "Cipla 2011." Harvard Business School Case 511-050, April 2011. (Revised April 2015.)
- 02 Mar 2010
- First Look
First Look: March 2
innovation in a wide range of other industries, including pharmaceuticals and biotechnology, IT and telecommunications, defense, chemicals, and agriculture. We believe that there are valuable lessons in this research for the energy...
View Details
Keywords:
Martha Lagace
- 03 Feb 2015
- First Look
First Look: February 3
field and other business fields complements the contributions from industrial organization economics (IO). These business fields also offer theoretical and empirical challenges to the IO paradigm, which dominates antitrust analysis. The...
View Details
Keywords:
Sean Silverthorne
- September 1990 (Revised November 1991)
- Case
Merck & Co., Inc. (B)
In late 1986, Merck revised its performance review and pay practices. The most important change was a shift from an absolute rating system to a forced-distribution system in which managers are forced to adhere to a given distribution of performance ratings. Other major...
View Details
Murphy, Kevin J. "Merck & Co., Inc. (B)." Harvard Business School Case 491-006, September 1990. (Revised November 1991.)
- April 2009
- Case
Merck: Managing Vioxx (A)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
This two-class case series allows students to stand in the shoes of CEO Ray Gilmartin during the unfolding stages of a reputational crisis. Merck's mission statement claims to "put patients first," but the company is widely criticized for putting profit before patient...
View Details
Keywords:
Ethics;
Crisis Management;
Reputation;
Decision Choices and Conditions;
Customers;
Business or Company Management;
Cost vs Benefits;
Corporate Accountability;
Business and Shareholder Relations;
Business and Stakeholder Relations;
Customer Focus and Relationships;
Pharmaceutical Industry
Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Merck: Managing Vioxx (A)." Harvard Business School Case 109-080, April 2009.
- 15 Jan 2013
- First Look
First Look: January 15
circumscribe citizen-employees, and they engage in production and trade. But individual corporations are no longer adequate to serve as the primary unit of analysis. Over the years, systems of distributed innovation-so-called business ecosystems-have become...
View Details
Keywords:
Sean Silverthorne
- November 2002
- Compilation
Four Principles of Biomedical Ethics: Definitions and Examples
By: Sandra J. Sucher
Introduces four principles of biomedical ethics, excerpted from Principles of Biomedical Ethics, Tom L. Beauchamp and James F. Childress (Oxford University Press, 2001). The principles provide a conceptual framework for the analysis and resolution of moral problems...
View Details
Keywords:
Framework;
Moral Sensibility;
Health Care and Treatment;
Distribution;
Problems and Challenges;
Research;
Emotions;
Management Analysis, Tools, and Techniques;
Pharmaceutical Industry;
Pharmaceutical Industry
Sucher, Sandra J. "Four Principles of Biomedical Ethics: Definitions and Examples." Harvard Business School Compilation 603-079, November 2002.
- February 2024
- Article
Representation and Extrapolation: Evidence from Clinical Trials
By: Marcella Alsan, Maya Durvasula, Harsh Gupta, Joshua Schwartzstein and Heidi L. Williams
This article examines the consequences and causes of low enrollment of Black patients in clinical
trials. We develop a simple model of similarity-based extrapolation that predicts that evidence is
more relevant for decision-making by physicians and patients when it...
View Details
Keywords:
Representation;
Racial Disparity;
Health Testing and Trials;
Race;
Equality and Inequality;
Innovation and Invention;
Pharmaceutical Industry
Alsan, Marcella, Maya Durvasula, Harsh Gupta, Joshua Schwartzstein, and Heidi L. Williams. "Representation and Extrapolation: Evidence from Clinical Trials." Quarterly Journal of Economics 139, no. 1 (February 2024): 575–635.
- 01 Oct 2001
- News
Guy de Chazal: Changing Focus
venture capital with Citicorp. "The industry was much, much smaller in those days," he says. "A few hundred million dollars a year, versus almost a hundred billion today." Drawing on his experience with Morgan Stanley since 1986, he...
View Details
Keywords:
Deborah Blagg
- June 2014 (Revised September 2014)
- Case
Johnson & Johnson: The Promotion of Wellness
By: John A. Quelch and Carin-Isabel Knoop
To create the world's healthiest workforce, diversified health care giant Johnson & Johnson (J&J) mandated participation in its "Culture of Health" program globally, customized by location, culture, and specific health needs to offer prevention-focused education,...
View Details
Keywords:
Healthcare;
Employee Motivation;
Transformation;
Ethics;
Health;
Human Resources;
Leadership;
Management;
Personal Development and Career;
Problems and Challenges;
Strategy;
Health Industry;
Health Industry;
Health Industry;
North and Central America;
Middle East;
Latin America;
Europe;
Asia
Quelch, John A., and Carin-Isabel Knoop. "Johnson & Johnson: The Promotion of Wellness." Harvard Business School Case 514-112, June 2014. (Revised September 2014.)
- February 2024
- Case
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no...
View Details
Keywords:
Commercialization;
Corporate Strategy;
Competitive Strategy;
Product Launch;
Health Testing and Trials;
Research and Development;
Pharmaceutical Industry;
Europe;
United States;
United Kingdom
Zuzul, Tiona, Kisha Lashley, and Gamze Yucaoglu. "Compass Pathways: Pioneering Psychedelic Treatment." Harvard Business School Case 724-412, February 2024.
- 15 Dec 2003
- Research & Ideas
The New Global Business Manager
now we see new competitors come from smaller countries that, because their home markets are too small to support them, are moving immediately onto the global stage. We also see whole industries that are being born global, particularly the...
View Details
Keywords:
by Cynthia Churchwell